FCGR3A and lymphoid neoplasm: It has been demonstrated that CD16-directed bi-specific (CD16×19) and tri-specific (CD16×19×22) scFv agents directly stimulate NK cells via CD16, potentiating NK cell lytic activity and cytokine release to attack lymphoid tumors (58, 59).